Skip to main content

View full-text article in PMC

. 2008 Mar 26;8:5. doi: 10.1186/1472-6874-8-5

Table 3.

Distribution of women with different quality of life scores in each arm of the EPHT Trial over time

	EQ-5D score
Survey year/trial arm	Minimum	1^stquartile	Median	3^rdquartile	Maximum
2nd year
Non-blind HT	0.30	0.80	0.90	1.00	1.00
Non-treatment	0.40	0.70	0.90	1.00	1.00
Blind HT	0.30	0.80	0.90	1.00	1.00
Blind placebo	0.30	0.80	0.90	1.00	1.00
Final
Non-blind HT	0.40	0.70	0.80	0.90	1.00
Non-treatment	0.30	0.70	0.80	0.90	1.00
Blind HT	0.30	0.70	0.80	0.90	1.00
Blind placebo	0.10	0.70	0.80	0.90	1.00

EQ-5D – quality of life according to EQ-5D score

HT – hormone therapy